The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
Top Cited Papers
Open Access
- 24 March 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 117 (12), 3421-3429
- https://doi.org/10.1182/blood-2009-11-255232
Abstract
The transcription factor STAT5 is an essential mediator of the pathogenesis of chronic myelogenous leukemia (CML). In CML, the BCR/ABL fusion kinaseKeywords
This publication has 36 references indexed in Scilit:
- Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cellsBlood, 2010
- Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemiaEMBO Molecular Medicine, 2010
- Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacementBlood, 2009
- Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3Blood, 2008
- The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaBlood, 2007
- STAT3 as a central mediator of neoplastic cellular transformationCancer Letters, 2006
- Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinationsBlood, 2006
- STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomasOncogene, 2006
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001